What Has Driven the Growth of the Extended-Release Drugs Market in Recent Years?
The extended-release drugs market has seen considerable growth due to a variety of factors.
•The market size for extended-release medicines has experienced swift expansion in the past few years. Its size is projected to rise from $63.11 billion in 2024 to $70.28 billion in 2025, marking a compound annual growth rate (CAGR) of 11.4%.
Enhancements in patient compliance, the prevalence of chronic diseases, increased efficacy, strategic patent protection, and biodegradable implants are significant factors contributing to this historical growth period.
What is the Market Size Forecast for the Extended-Release Drugs Market?
The extended-release drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the extended-release drugs market is projected to experience accelerated growth, expanding to $113.05 billion in 2029 with a compound annual growth rate (CAGR) of 12.6%.
Factors contributing to this growth during the forecast period include approaches to personalized medicine, drug development focused on patients, an increase in lifestyle diseases, drug repurposing, and worldwide access to extended-release therapies. Additionally, significant trends influencing this period entail new pharmaceutical innovations, breakthroughs in drug delivery systems, advancements in nanotechnology, the utilization of 3D printing in drug concoctions, the application of artificial intelligence, and emphasis on environmental sustainability.
What Factors Are Driving Growth In The Extended-Release Drugs Market?
The growth of the extended-release drug market is likely to be fuelled by the rising prevalence of chronic diseases. Chronic diseases are defined as conditions that last for a year or more, requiring ongoing medical attention, limiting daily activities, or both. These conditions may include heart disease, cancer, obesity, and diabetes. Extended-release drug delivery systems aim to maintain a steady amount of medication in the body over an extended period. This system aids in ensuring a stable therapeutic effect and preventing the inconsistent drug levels that can occur with immediate-release medications. For instance, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected in January 2023 that by 2050, the population of individuals aged 50 years and older suffering from at least one chronic disease will skyrocket by 99.5%, equivalent to 142.66 million people. Consequently, the escalating prevalence of chronic diseases is stimulating the expansion of the extended-release drug market.
What Are The Main Segments Of The Global Extended-Release Drugs Market?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Pre-Book The Extended-Release Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Extended-Release Drugs Market?
Product innovation is emerging as a predominant trend in the extended-release drug marketplace. Top companies in this arena are focusing on the creation of novel offerings to cement their stand in the market. For instance, Zydus Pharmaceuticals (USA) Inc., a generics manufacturer based in the US, rolled out Topiramate extended-release capsules used in epilepsy treatment in July 2022. The US Food and Drug Administration (USFDA) had earlier given the green light to commercialize Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. The company is the pioneer to gain final approval and commencement of Topiramate extended-release capsule production. These Topiramate extended-release capsules have dual approval for people suffering from partial onset or primary generalized tonic-clinic seizure.
Who Are the Key Players in the Extended-Release Drugs Market?
Major companies operating in the extended-release drugs market include:
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi SA
• GlaxoSmithKline PLC
• AstraZeneca Plc
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceuticals Inc.
• Eastman Chemical Company
• Catalent Pharma Solutions Inc.
• Sun Pharmaceutical Industries Limited
• Purdue Pharma LP
• Amneal Pharmaceuticals Inc.
• Endo Pharmaceuticals Inc.
• Mallinckrodt LLC
• Allergan plc
• Hisamitsu Pharmaceutical Co. Inc.
• Janssen Pharmaceuticals Inc.
• Noven Pharmaceuticals Inc.
• Mayne Pharma Group Ltd.
• Neos Therapeutics Inc.
• Ardena Holding NV
• UPM Pharmaceuticals Inc.
• Oakwood Laboratories LLC
• Roxane Laboratories Inc.
• Lavipharm Laboratories Inc.
• Watson Pharmaceuticals Inc.
What Is The Most Dominant Region In The Extended-Release Drugs Market?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
